LSD Analogues for Health & Longevity - Quick Reference Sheet

LSD Analogues for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

LSD analogues, chemical relatives of the mind-altering drug LSD sold as unregulated research chemicals, draw interest for anxiety, problem drinking and longevity. Appeal rests mostly on supervised LSD trials; human analogue data come from a tiny dosing study, surveys and case reports; small repeated doses have not clearly outperformed placebo. Risks: frightening experiences, heart strain, rare lasting loss of touch with reality in vulnerable people, dangerous lithium reactions, mislabelled products. (Full Review)

Protocol

Reference regimen (LSD trials)
1–2 sessions of 100–200 µg LSD
Supervised, with preparation and follow-up; no analogue has a trial-tested regimen
1P-LSD dose equivalence
100 µg 1P-LSD contains ≈70 µg LSD
In its usual salt form, by molecular weight; with near-complete conversion, users treat it as roughly equal in strength to LSD
Microdosing schedule
10–20 µg every third day
For 4–10 weeks, popularized by James Fadiman; controlled LSD trials used 5–26 µg every 3–4 days
Time to effect
Anxiety improvement
4–16 weeks
Measured after one dose in LSD trials
Longer sleep
Night after dosing
After 10 µg LSD microdoses every third day
Acute effects
Onset within 30–60 minutes
Peak at 2–4 hours; last 8–12 hours

Benefits

Contraindications
  • Personal history of a psychotic disorder or bipolar I disorder, or a first-degree relative with either
  • Resting blood pressure ≥140/90 mmHg despite treatment, heart attack or stroke within the past 6 months, significant arrhythmia, or known heart valve disease
  • Pregnancy or breastfeeding
  • Current lithium treatment
  • Epilepsy or any history of unprovoked seizures
  • Adolescents under 18 years
  • Severe liver impairment (Child-Pugh Class C)
Key Interactions
  • SSRIs and SNRIs (serotonin-boosting antidepressants: sertraline, escitalopram, venlafaxine; caution)
  • Monoamine oxidase inhibitors (older antidepressants: phenelzine, tranylcypromine; caution)
  • Strong CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine; monitor)
  • 5-HT2A blockers and antipsychotics (ketanserin, risperidone, quetiapine; monitor)
  • Triptans and ergot drugs (sumatriptan, ergotamine, methysergide; caution)
  • Tramadol (caution)
  • Dextromethorphan, over-the-counter cough suppressant (caution)
  • Decongestants (pseudoephedrine, phenylephrine; caution)
  • Serotonin-boosting supplements (St John's wort, 5-HTP, L-tryptophan, SAMe; caution)
  • Stimulating supplements (high-dose caffeine, yohimbine, synephrine; monitor)
  • Other substances (MDMA or ecstasy, amphetamine, cocaine, cannabis, alcohol; caution)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Acute anxiety, confusion and dangerous behaviour; raised heart rate, blood pressure and body temperature; nausea and headache; lingering visual disturbances; persistent psychosis or mania in vulnerable people; worsening depression or suicidal behaviour in psychiatric patients; blood vessel constriction and high blood pressure with LSA; misidentified or mislabelled products; psychoactive effects of 2-Br-LSD
  • Speculative: Heart valve damage with frequent microdosing; unknown toxicity of newer analogues

Monitoring

Marker Target Why
Resting blood pressure <120/80 mmHg; dosing deferred at ≥140/90 mmHg Cardiovascular strain
Resting heart rate 50–70 beats/min; dosing deferred if >100 Stimulation, arrhythmia risk
QTc interval on ECG (heart electrical tracing) <430 ms (men), <450 ms (women) Heart rhythm safety
Heart valve echocardiogram (heart ultrasound) No valve leakage or thickening Heart valve risk
ALT (liver enzyme) <25 U/L Liver clearance capacity
GAD-7 anxiety score <5 Anxiety response
PHQ-9 depression score <5 Depression response
CYP2D6 genotype Normal metabolizer Predicts exposure and duration

Cadence: Baseline before starting; blood pressure and heart rate before dosing and at 2–3 hours on each dosing day; symptom questionnaires at 1, 4 and 12 weeks after a full-dose session; blood pressure, heart rate and liver enzymes every 3–6 months during repeated use; echocardiogram every 12 months for microdosing beyond 6 months

Qualitative Assessment

  • Sustained improvement in mood, anxiety and emotional flexibility beyond the acute effects
  • Sleep quality and duration, especially the night after dosing
  • Energy, focus and cognitive clarity in daily tasks
  • Absence of lingering visual disturbances, persistent anxiety or unusual thoughts
  • Changes in alcohol or other substance use
  • Frequency and severity of cluster headache attacks, where relevant